# CSL Seqirus

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/csl-seqirus
Canonical HTML page: https://getyourbrief.com/entity/csl-seqirus

## Recent coverage (4 stories, network-wide)

### US Flu Vaccine Effectiveness Drops Below Historical Averages for 2025-26 Season
2026-03-14 23:47:43 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Preliminary CDC data indicates that the 2025-2026 influenza vaccine provided lower-than-expected protection, with effectiveness falling to approximately 32%. The findings highlight a significant mismatch between the vaccine's composition and the dominant H3N2 variant, sparking calls for faster manufacturing platforms.
Full story: https://gethealthbrief.com/story/flu-vaccine-effectiveness-decline-2026

### Egg Prices Plunge as Avian Flu Recedes, Shifting Focus to Vaccine R&D
2026-03-14 17:01:49 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Full story: https://getbiobrief.com/story/egg-prices-avian-flu-biotech-impact

### Biotech Execution in Focus: Arcturus and Rigel Set for Q4 Earnings Results
2026-03-02 22:55:18 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are preparing to report Q4 2025 results, highlighting a pivotal shift from clinical development to commercial execution. Investors are focused on Arcturus's mRNA vaccine rollout in Japan and Rigel's integration of its expanded oncology portfolio.
Full story: https://getfinancebrief.com/story/arcturus-rigel-q4-2025-earnings-preview

### Arcturus and Rigel Q4 Previews: mRNA Innovation vs. Oncology Commercialization
2026-03-02 22:54:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Arcturus Therapeutics and Rigel Pharmaceuticals are set to report Q4 2025 results, highlighting a pivotal year for mRNA platform validation and oncology market expansion. Investors are focused on Arcturus's sa-mRNA commercial progress in Japan and Rigel's sales trajectory for its flagship hematology treatments.
Full story: https://getbiobrief.com/story/arcturus-rigel-q4-2025-earnings-preview

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.